| Literature DB >> 33670748 |
Tomohiro Yamashita1,2, Sawako Kamikaseda2, Aya Tanaka2, Hidetoshi Tozaki-Saitoh2,3, Jose M M Caaveiro1, Kazuhide Inoue2, Makoto Tsuda2,3.
Abstract
P2X7 receptors (P2X7Rs) belong to a family of ATP-gated non-selective cation channels. Microglia represent a major cell type expressing P2X7Rs. The activation of microglial P2X7Rs causes the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β). This response has been implicated in neuroinflammatory states in the central nervous system and in various diseases, including neuropathic pain. Thus, P2X7R may represent a potential therapeutic target. In the present study, we screened a chemical library of clinically approved drugs (1979 compounds) by high-throughput screening and showed that the Ca2+ channel blocker cilnidipine has an inhibitory effect on rodent and human P2X7R. In primary cultured rat microglial cells, cilnidipine inhibited P2X7R-mediated Ca2+ responses and IL-1β release. Moreover, in a rat model of neuropathic pain, the intrathecal administration of cilnidipine produced a reversal of nerve injury-induced mechanical hypersensitivity, a cardinal symptom of neuropathic pain. These results point to a new inhibitory effect of cilnidipine on microglial P2X7R-mediated inflammatory responses and neuropathic pain, proposing its therapeutic potential.Entities:
Keywords: IL-1β; P2X7R; cilnidipine; high-throughput screening; inflammation; microglia; neuropathic pain
Year: 2021 PMID: 33670748 DOI: 10.3390/cells10020434
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600